Regeneron said Monday it will “prioritize the privacy, security and ethical use” of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt 23andMe Holding Co.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Drugmaker Regeneron Pharmaceuticals says it will comply with privacy policies regarding the use of customer data. 23andMe's bankruptcy filings had drawn scrutiny from lawmakers who warned that millions of customers' genetic data could be sold to unscrupulous buyers.